Skip to main content
NVDA+1.07%AAPL-0.33%MSFT-0.63%GOOGL-1.06%AMZN+0.78%TSM+1.40%SPCX-0.40%META-0.68%AVGO+2.33%TSLA+1.23%LLY+0.45%BRK-B+1.17%MU+2.54%SKHY+4.09%WMT+0.33%JPM+0.74%AMD+2.80%XOM+0.73%V-0.92%JNJ+0.94%ASMLa+1.77%MA-1.62%ABBV+0.40%INTC+4.04%CVX-0.51%1398.HK+2.15%0700.HK-0.31%COST+0.18%CSCO+3.51%KO-0.01%ORCL-0.08%PG-0.68%UNH-1.77%1816.HK+1.32%BAC-0.08%3988.HK+0.66%HD-0.14%CAT+0.75%0857.HK-0.98%PM+1.20%0939.HK+0.81%AP2d+2.40%AMAT+2.74%1288.HK+0.60%GE+0.98%LRCX+3.22%DELL+2.37%0005.HK-5.56%HSBA.L-6.86%NVS+1.78%NZDJPY+0.69%NZDMXN+0.64%USDJPY+0.61%AUDJPY+0.58%EURNZD-0.55%NZDCHF+0.49%CADJPY+0.49%EURUSD-0.46%AUDDKK+0.44%EURSEK-0.44%EURAUD-0.42%NZDSGD+0.42%USDCHF+0.41%GBPTRY+0.41%AUDCHF+0.40%GBPNZD-0.40%GBPUSD-0.33%GBPHKD+0.32%CHFSEK-0.32%NOKJPY+0.31%EURNOK-0.31%EURCAD-0.30%GBPAUD-0.30%GBPMXN-0.28%CADCHF+0.28%GBPJPY+0.27%EURCNH-0.24%AUDSGD+0.24%USDSEK-0.23%USDMXN+0.23%EURHKD-0.22%USDDKK+0.21%CHFJPY+0.21%USDPLN+0.21%NZDCAD+0.21%GBPCAD-0.21%EURZAR-0.20%EURSGD-0.20%SGDJPY+0.19%CHFNOK-0.18%USDTRY+0.18%EURJPY+0.17%USDILS+0.16%USDCAD+0.14%AUDNOK+0.13%EURGBP-0.12%AUDNZD-0.11%AUDCAD+0.10%USDNOK-0.10%GBPSGD-0.09%GBPZAR-0.08%CHFSGD-0.07%GBPCHF+0.07%NZDUSD+0.07%EURCHF-0.06%USDTHB-0.04%USDCOP-0.04%USDHKD+0.03%AUDUSD-0.03%USDCNH-0.03%USDZAR+0.03%USDSGD+0.01%EURCZK+0.01%PLNJPY+0.01%EURPLN0.00%EURDKK0.00%COFFEE-1.83%COCOA+1.20%SUGAR+1.02%HG1+0.94%XPTUSD-0.71%XAGUSD-0.59%GAGUSD-0.59%UKOIL-0.30%USOIL-0.29%GAUUSD+0.15%XAUUSD+0.15%XNGUSD+0.14%BTCUSD+0.54%ETHUSD+23.96%USDTUSD+0.01%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.06%ZECUSDT+3.59%DOGEUSD+20.65%XMRUSDT-0.08%LINKUSD+25.58%BCHUSDT+1.65%XLMUSD+0.04%UNIUSD-0.19%LTCUSD+17.89%SUIUSD+0.83%HBARUSDT-0.82%TONUSD+41.71%TAOUSDT+0.26%AAVEUSD-1.92%DOTUSDT-1.19%ICPUSDT-0.84%ONDOUSDT-0.24%WLDUSDT+0.83%ARBUSDT+0.60%JUPUSDT+0.30%INJUSDT+0.45%ATOMUSDT-0.21%STXUSDT-0.10%TIAUSDT-2.89%PYTHUSDT-2.39%FETUSDT+1.64%SEIUSDT+0.54%IMXUSDT+0.07%GRTUSDT-0.27%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+1.05%POLUSDT-0.86%AXSUSDT+0.20%EOSUSDT+2.21%FARTCOINUSDT+2.30%DYDXUSDT+0.44%GALAUSDT-0.75%ORDIUSDT+1.02%RONINUSDT+0.02%NOTUSDT+1.92%NVDA+1.07%AAPL-0.33%MSFT-0.63%GOOGL-1.06%AMZN+0.78%TSM+1.40%SPCX-0.40%META-0.68%AVGO+2.33%TSLA+1.23%LLY+0.45%BRK-B+1.17%MU+2.54%SKHY+4.09%WMT+0.33%JPM+0.74%AMD+2.80%XOM+0.73%V-0.92%JNJ+0.94%ASMLa+1.77%MA-1.62%ABBV+0.40%INTC+4.04%CVX-0.51%1398.HK+2.15%0700.HK-0.31%COST+0.18%CSCO+3.51%KO-0.01%ORCL-0.08%PG-0.68%UNH-1.77%1816.HK+1.32%BAC-0.08%3988.HK+0.66%HD-0.14%CAT+0.75%0857.HK-0.98%PM+1.20%0939.HK+0.81%AP2d+2.40%AMAT+2.74%1288.HK+0.60%GE+0.98%LRCX+3.22%DELL+2.37%0005.HK-5.56%HSBA.L-6.86%NVS+1.78%NZDJPY+0.69%NZDMXN+0.64%USDJPY+0.61%AUDJPY+0.58%EURNZD-0.55%NZDCHF+0.49%CADJPY+0.49%EURUSD-0.46%AUDDKK+0.44%EURSEK-0.44%EURAUD-0.42%NZDSGD+0.42%USDCHF+0.41%GBPTRY+0.41%AUDCHF+0.40%GBPNZD-0.40%GBPUSD-0.33%GBPHKD+0.32%CHFSEK-0.32%NOKJPY+0.31%EURNOK-0.31%EURCAD-0.30%GBPAUD-0.30%GBPMXN-0.28%CADCHF+0.28%GBPJPY+0.27%EURCNH-0.24%AUDSGD+0.24%USDSEK-0.23%USDMXN+0.23%EURHKD-0.22%USDDKK+0.21%CHFJPY+0.21%USDPLN+0.21%NZDCAD+0.21%GBPCAD-0.21%EURZAR-0.20%EURSGD-0.20%SGDJPY+0.19%CHFNOK-0.18%USDTRY+0.18%EURJPY+0.17%USDILS+0.16%USDCAD+0.14%AUDNOK+0.13%EURGBP-0.12%AUDNZD-0.11%AUDCAD+0.10%USDNOK-0.10%GBPSGD-0.09%GBPZAR-0.08%CHFSGD-0.07%GBPCHF+0.07%NZDUSD+0.07%EURCHF-0.06%USDTHB-0.04%USDCOP-0.04%USDHKD+0.03%AUDUSD-0.03%USDCNH-0.03%USDZAR+0.03%USDSGD+0.01%EURCZK+0.01%PLNJPY+0.01%EURPLN0.00%EURDKK0.00%COFFEE-1.83%COCOA+1.20%SUGAR+1.02%HG1+0.94%XPTUSD-0.71%XAGUSD-0.59%GAGUSD-0.59%UKOIL-0.30%USOIL-0.29%GAUUSD+0.15%XAUUSD+0.15%XNGUSD+0.14%BTCUSD+0.54%ETHUSD+23.96%USDTUSD+0.01%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.06%ZECUSDT+3.59%DOGEUSD+20.65%XMRUSDT-0.08%LINKUSD+25.58%BCHUSDT+1.65%XLMUSD+0.04%UNIUSD-0.19%LTCUSD+17.89%SUIUSD+0.83%HBARUSDT-0.82%TONUSD+41.71%TAOUSDT+0.26%AAVEUSD-1.92%DOTUSDT-1.19%ICPUSDT-0.84%ONDOUSDT-0.24%WLDUSDT+0.83%ARBUSDT+0.60%JUPUSDT+0.30%INJUSDT+0.45%ATOMUSDT-0.21%STXUSDT-0.10%TIAUSDT-2.89%PYTHUSDT-2.39%FETUSDT+1.64%SEIUSDT+0.54%IMXUSDT+0.07%GRTUSDT-0.27%OPUSDT-0.20%WIFUSDT-0.61%IOTAUSDT+1.05%POLUSDT-0.86%AXSUSDT+0.20%EOSUSDT+2.21%FARTCOINUSDT+2.30%DYDXUSDT+0.44%GALAUSDT-0.75%ORDIUSDT+1.02%RONINUSDT+0.02%NOTUSDT+1.92%
PM

Prime Medicine, Inc. (PRME)

NASDAQ • Healthcare

$3.61
-$0.06 (-1.6%)
Market closed

Last close at October 26, 2026 at 20:00 UTC

Open$3.68
Day Range$3.57 - $3.7
Avg. Volume (3M)4.9M
Market Cap$654.7M
52 Week Range
$2.67$5.11

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$1.1M100%
Gross Profitminus cost of goods$1.1M100%

Fundamentals & Financials

Revenue (TTM)
$4M
Net Income (TTM)
-$187.8M
EPS (TTM)
-$1.1
ROA (TTM)
-75.45%
Current Ratio
3.05

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+12.0%Q1 2026-$0.22
-16.7%Q2 2026-$0.28
+6.7%Q3 2026-$0.24

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +6.7%

Prime Medicine topped EPS expectations in the second fiscal quarter of 2026, reported August 6, 2026, with EPS of -$0.24 topping the -$0.26 estimate by $0.02 as revenue rose ~4% to about $1.2 million (up from roughly $1.1 million a year ago). The quarter’s results reflected its biotech profile centered on prime editing programs, with gross profit also around $1.2 million while operating income was -about $43.3 million. Net income improved year over year to roughly -$42.1 million (from about -$52.6 million), alongside EPS up ~42% from -$0.41 a year ago. For the next period, consensus calls for EPS of -$0.24 on revenue of $1.3 million.

Next report — what to expect

Prime Medicine, Inc. (PRME) reports on November 6, 2026. Wall Street expects EPS of -$0.239 on revenue of $1.3 million. As trailing context, revenue grew +3.5% year over year last quarter. PRME has beaten EPS in 3 of its 8 most recent quarters, so focus will be on updates versus consensus.

View full earnings history

About Prime Medicine, Inc.

Prime Medicine, Inc. is a NASDAQ-listed biotechnology company in healthcare that develops genetic therapies built on gene editing technology. The company is a small-cap biotech and has focused its platform on prime editing, a gene-writing approach aimed at making precise changes to DNA.

Name
Prime Medicine, Inc.
CEO
Allan Reine
Website
www.primemedicine.com
Industry
Healthcare
Year Founded
2019
Employees
146

Today's Snapshot

AI-generated

PRME closed 1.6% lower at 3.61.

Trading Volume

Below 10d avg (4.1M)

2.5M

vs S&P 500 Today

Underperforming Market

-2.33%

Updated: October 27, 2026 at 12:27 UTC

Technical Indicators

5 Buy2 Neutral1 Sell
PRME shows a constructive technical profile driven by a clear trend and modest momentum while volume and volatility temper conviction. ADX above 30 points to a meaningful trend, and a positive MACD complements neutral momentum readings around mid-range, indicating gradual upside bias. The stock trades at about 3.61, sitting near its short-term average and above several medium- and long-term moving averages, which supports the bullish lean, however on-balance volume is negative and ATR’s near 9% implies elevated volatility. Technical takeaway: Strong Buy bias supported by trend strength and supportive moving averages.
All signals
  • EMA (5 indicators)$3.40 - $3.64
    Buy
  • RSI (14)52.32
    Neutral
  • Stochastic %K (14, 3, 3)58.57
    Neutral
  • MACD Level (12, 26)0.12
    Buy

Peers & Related Assets

CRSPCRISPR Therapeutics AG
$49.01-0.8%
BEAMBeam Therapeutics Inc.
$23.79-1.1%
NTLAIntellia Therapeutics, Inc.
$11.26+0.5%
DSGNDesign Therapeutics, Inc.
$10.34+1.0%
EDITEditas Medicine, Inc.
$2.40.0%
SCTXScribe Therapeutics Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.